Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
September 13, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration...
Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis
Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13...
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
CAMBRIDGE, Mass., Sept. 18, 2024. Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results...
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson...
Greater Adherence to MIND Diet Linked to Reduced Cognitive Impairment
Greater Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet adherence is associated with a reduced...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe...
Trends in Prehospital Encounters for Youth Opioid Overdose Identified
Prehospital encounters for youth opioid overdoses increased before the COVID-19 pandemic, then increased with onset, and then stabilized, according to...
Long-Term Outcomes Good for Face Transplant Recipients, Study Finds
There have been 50 face transplants performed in 11 countries since the surgery was pioneered back in 2005, and long-term outcomes have been favorable,...
Buildup of Metals in Body Can Worsen Heart Disease
Cadmium, uranium, cobalt: These and other metals found in the environment can collect in the body and exacerbate heart disease, new research suggests. "Our...
FDA Expands Use of Breast Cancer Drug Kisqali
Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's...
Feeling Content Helps Shield You From Heart Attack, Stroke
Folks who are content with what they’ve got could be less likely to suffer a heart attack or stroke, a new study suggests. “Our findings support...
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30
HONG KONG, Sept. 17, 2024. Ascletis Pharma Inc. ("Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I clinical...
Why Beans Are a Natural Superfood
Beans may sometimes give you gas, but one expert says that shouldn't stop you from finding ways to include them in your diet. Why? Because they are packed...
Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause
The FDA is warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury. If...
Recently Added
Recently added consumer and prescribing information: Pavblu, Livdelzi, Yorvipath, Crexont, Lymphir, Epysqli, Pyzchiva, Ahzantive, Ohtuvayre, Sofdra
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Ocrevus Zunovo Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) is a CD20-directed cytolytic antibody and hyaluronidase combination used for the...
- Ebglyss Ebglyss (lebrikizumab-lbkz) is a targeted IL-13 inhibitor used for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults...
- Pavblu Pavblu (aflibercept-ayyh) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Eylea indicated for the treatment of...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...